Diamyd Logo

Ongoing Phase III Trials for type 1 diabetes

Diamyd Medical is currently conducting two clinical Phase III studies in type 1 diabetes: one in Europe and one in the US. The purpose with the studies is to determine whether Diamyd® can preserve the body's own insulin producing capacity in persons diagnosed with type 1 diabetes within in the past three months.
  Phase III Trials - USA   Phase III Trials - Europe

Ongoing Phase I Trials with NTDDS NP2
A Phase I clinical trial with NTDDS NP2. The purposes of this study is to examine the safety and efficacy of NP2 (a non-replicating HSV-based vector expressing enkephalin) in patients with cancer pain.


Ongoing investigator initiated trials
  • A US combination trial with Diamyd® and drugs that are believed to stimulate new beta cell growth. The aim of the combination therapy is try to restore lost insulin-producing capacity in type 1 diabetes patients. The trial is sponsored by National Institutes of Health, Washington, USA.

  • A Swedish prevention study with Diamyd® in children at high risk to develop type 1 diabetes. The aim is to evaluate safety and whether Diamyd® can delay or stop the autoimmune process leading to type 1 diabetes and thereby prevent the disease. The study is sponsored in part by the Swedish Research Council, UMAS Funds and the Skåne County Fund for research and Development.

  • A prevention study with Diamyd® in Norway. The objective of the study is to investigate the disease process before type 1 diabetes onset. A unique feature of the study is that tissue samples from the pancreas are taken. Analysis of these tissue samples can provide direct insight into how Diamyd® reduces the destruction of beta cells, i.e. the cells that produce insulin. The trial is sponsored by Helse-SørØst, Oslo University Hospital and University of Oslo, Norway.

  • TrialNet intervention study with Diamyd®. A group of international diabetes specialists and a network of opinion leaders funded by National Institutes of Health (NIH)/National Institute of Diabetes, Digestive and Kidney diseases (NIDDK), who are exploring ways to prevent, delay and reverse the progression of type 1 diabetes, has chosen Diamyd® for a 126 patient study in recent onset type 1 patients. The purpose is to determine whether treatment with multiple injections of Diamyd® will preserve the body's own insulin production. A thorough immunological assessment is also pursued in conjunction with the study.